Neurol. praxi. 2020;21(1):46-49 | DOI: 10.36290/neu.2020.025

Polyneuropathy associated with levodopa/carbidopa intestinal gel infusion (LCIG)

MUDr. Milan Grofik, PhD., MUDr. Monika Turčanová Koprušáková, PhD., prof. MUDr. Egon Kurča, PhD., FESO
Neurologická klinika, Jesseniova lekárska fakulta UK a UNM Martin

LCIG is an effective treatment for the advanced stage of Parkinson's disease. Serious complication of this treatment is polyneuropathy, which can signifficantly influenced motor and non-motor functions of the patient and the quality of life. In most of the cases there is a metabolic cause of polyneuropathy due to the usage of levodopa, associated with elevation of homocysteine and deficiency of vitamins B. In case of acute polyneuropathy, it is necessary to exclude Guillain-Barré Syndrome and discontinue LCIG treatment. Each patient should be examined for polyneuropathy before the initiation of LCIG therapy and also during the treatment.

Keywords: LCIG, levodopa, polyneuropathy, B-vitamins.

Published: March 30, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Grofik M, Turčanová Koprušáková M, Kurča E. Polyneuropathy associated with levodopa/carbidopa intestinal gel infusion (LCIG). Neurol. praxi. 2020;21(1):46-49. doi: 10.36290/neu.2020.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Antonini A, Poewe W, Ray Chaudhuri K, Jech R, Pickut B, Pirto Z, Szasz J, Valldeoriola F, Winkler Ch, Bergmann L, Yegin A, Onuk K, Barch D, Odin P on behalf of the GLORIA study co-investigators. Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism Relat Disord 2017; 45: 13-20. Go to original source... Go to PubMed...
    2. Comi C, Magistrelli L, Oggioni GD, Carecchio M, Fleetwood T, Cantello R, Mancini F, Antonini A. Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism and Related Disorders 2014; 20: 1329-1334. Go to original source...
    3. Cossu G, Ceravolo R, Zibetti M, Arca R, Ricchi V, Paribello A, Murgia D, Merola A, Romagnolo A, Nicoletti V, Palermo G, Mereu A, Lopiano L, Melis M, Abbruzzese G, Bonuccelli U. Levodopa and neuropathy risk in patients with Parkinson's disease: effect of COMT inhibition. Parkinsonism and Related Disorders 2016; 27: 81-84. Go to original source...
    4. European commission health & consumer protection directorate-general. Directorate C - Scientific Health Opinions. Unit C3 - Management of scientific committees II. Opinion of the Scientific Committee on Food on the Tolerable Upper Intake Level of Vitamin B6. 2000
    5. Fernandez HH, Boyd JT, Fung VSC, Lew MF, Rodriguez RL, Slevin JT, Standaert DG, Zadikoff C, Vanagunas AD, Chatamra K, Eaton S, Facheris MF, Hall C, Robieson WZ, Benesh J, Espay AJ. Long-term safety and efficacy of levodopa-carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders 2018; 33(6): 928-936. Go to original source... Go to PubMed...
    6. Galazky I, Schoof J, Stallforth S, Kupsch A, Heinze H J, Kluge C. Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment. Parkinsonism Relat Disord 2014, 20: 125-127. Go to original source...
    7. Havránková P, Baláž M, Bareš M, Kaiserová M, Minár M, Haň V, Necpál J, Grofik M, Klempír J, Roth J, Gmitterová K, Skička L, Růžička E, Bareš M, Rektorová I, Kaňovský P Valkovič P, Škorvánek M, Kurča E, Jech R. Výskyt neuropatie u pacientů s Parkinsonovou nemocí léčených Duodopou v České a Slovenské republice. Cesk Slov Neurol N 2018; 81/114 (Suppl 2).
    8. Jugel C, Ehlen F, Taskin B, Marzinzik F, Müller T, Klostermann F. Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS ONE 2013; 8: e66639. doi: 10.1371/journal.pone.0066639. Go to original source... Go to PubMed...
    9. Kocer B. Guven H, Comoglu SS. Homocysteine levels in Parkinsons Disease: is entacapone effective? Biomed Res Int 2016; 2016: 7563705. Go to original source... Go to PubMed...
    10. Loens S, Chorbadzhieva E, Kleimann A, Dressler D, Schrader C. Effects of levodopa/ carbidopa intestinal gel versus oral levodopa/carbidopa on B vitamin levels and neuropathy. Brain Behav 2017; 7(5): e00698. doi: 10.1002/brb3.698. eCollection 2017 May. Go to original source... Go to PubMed...
    11. Mancini F, Comi C, Oqqioni GD, Pacchetti C, Calandrella D, Coletti Moja M, Riboldazzi G, Tunesi S, Dal Fante M, Manfredi L, Lacerenza M, Cantello R, Antonini A. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2014; 20: 27-31. Go to original source...
    12. Mars H. Levodopa, carbidopa, and pyridoxine in Parkinson's Disease. Metabolic Interactions. Arch Neurol 1974; 30: 444 - 447. Go to original source...
    13. Müller T, van Laar T, Cornblath DR, Odin P, Klostermann F, Grandas FJ, Ebersbach G, Urban PP, Valldeoriola F, Antonini A. Peripheral neuropathy in Parkinson´s disease: levodopa exposure and inplications for duodenal delivery. Parkinsonism Relat Disord 2013; 19: 501-517. Go to original source...
    14. Nevrlý M, Kaňovský P, Vranová H, Nestrašil I, Langová K. Ovlivnení plazmatické hladiny homocysteinu u pacientu s Parkinsonovou chorobou terapií L-DOPA a entacaponem. Cesk Slov Neurol N 2008; 71/104: 55-60.
    15. Santos-Garcia D, de la Fuente-Fernández R, Valldeoriola F, Palasí A, Carrillo F, Grande M, Mir P, De Fabregues O, Casanova J. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert. J Neurol 2012; 259: 1668-1672. Go to original source... Go to PubMed...
    16. Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson's disease: features, pathogenesis and management. J Neurol Neurosurg Psychiatry 2015; 86(5): 490-495. Go to original source...
    17. Valkovic P, Benetin J, Blazícek P, Valkovicová L, Gmitterová K, Kukumberg P. Reduced plasma homocysteine levels in levodopa/entacapone treated Parkinson patients. Parkinsonism Relat Disord 2005; 11(4): 253-256. Go to original source...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.